This gamut of antibiotics market has always maintained high profit returns on the back of several pharmaceutical blockbusters. Popular antibiotic compounds such as fluoroquinolone and cephalosporin have constantly gained maximum adoption over the years, thus contributing massively towards stable growth in global antibiotics market. However, with several generic products emerging and steady adoption of the same over the years owing to large unmet medical gaps as well as antibiotic abuse, the global antibiotics market is likely to face some still water stagnancy in forthcoming years.

Antibiotic resistance is a persistent bottleneck, denting growth significantly in global antibiotics market. Measurement indices such as Drug Resistance Indices which are employed to monitor antibiotic consumption and resistance patterns have been in use on the back of WHO mandate.

Several countries are closely following these measurement techniques to trace novel opportunities in antibiotic market, by primarily addressing instances of antibiotic threat. United Nations research finding on drug resistance suggests need for exemplary alterations in drug resistance, failing which can render extreme fatality, amounting to over 10 million human deaths in by 2050.Over use or abuse of lifesaving antibiotic drugs can also trigger bacterial resistance making therapeutics a challenge, owing to the adaptive capabilities of disease causing bacteria. The WHO echoes similar, stating that common health deficiencies and diseases such as TB, pneumonia and the like are fast becoming more challenging to treat owing to antibiotic resistance and post antibiotics era.

As antibiotic drug manufacturing is tedious marketing them at high prices is common to keep further R&D expeditions in antibiotics space flourishing. However, this leads to generic formulations and thus snubbing the market share of blogbuster antibiotic drugs.

Emergence of Superbugs and Gradual Drug Adaptation Cited in Bacteria Threatens Steady Growth

The challenge in tandem with proliferating risks of antibiotics resistance are likely to incur setbacks in antibiotics market. Antibiotic resistance is underpinning the steady decline in therapeutics. Countries such the US is registering high rates of antibiotic resistance, as high as 2.8 million case annually. The developments have underscored massive medical expenses and tremendous medical and emotional burden in recent years, thus necessitating R&D advances in antibiotics space. Owing to sale hiccups of antibiotic drugs, several high profit companies have exited antibiotics market, while several start-ups are declaring bankruptcy.

One of the notable developments in antibiotics market is the growing reliance on antibiotics stewardship programs which are being touted as necessary strategies to freeze antimicrobial resistance. Countries such as the US are implementing these programs to remain ahead in the graph of antibiotics market growth. Several frontline players have invested significantly in novel R&D expeditions to enhance pipeline potential of antibiotics drugs. Additionally, the growth spurt in antibiotics market is also connected to frequent emergence of new market aspirants eying major disruptions in terms of novel formulations. Government initiatives towards improved healthcare infrastructure, more emphatically across mid and low income countries is further estimated to twin the growth trail, allowing global antibiotics market to grow incessantly through the forecast span.